Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Fresenius Medical (FMS) to EUR 36 from EUR 37 and keeps an Underweight rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target lowered to EUR 44 from EUR 46 at Deutsche Bank
- Weak Operating Momentum, Limited Earnings Visibility, and 2026 Headwinds Drive Underperform (Sell) Rating and Price Target Cut to €32
- Fresenius Medical price target lowered to EUR 39.50 from EUR 48.50 at Citi
- Fresenius Medical downgraded to Neutral from Buy at Goldman Sachs
- Fresenius Medical Care Accelerates Second Tranche of €1 Billion Share Buyback